Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease

Andrew McGarry, Michael R. Hayden, Karl Kieburtz et al.|Journal of Huntington s Disease|2020

Cited by 22